According to recent evidence about boosted protease inhibitors (PIs/r)-simplified regimens, the combination of 3TC and DRV/r 800/100 mg could represent a feasible option for optimizing antiretroviral therapy (ART) in treatment-experienced HIV+ patients.

Borghetti, A., Mondi, A., Piccoli, B., Gagliardini, R., Lamonica, S., Ciccarelli, N., D'Avino, A., Pallavicini, F., Cauda, R., De Luca, A., Fabbiani, M., Di Giambenedetto, S., Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre, Abstract de <<HIV Drug Therapy Glasgow Congress 2014>>, (Glasgow, 02-06 November 2014 ), <<JOURNAL OF THE INTERNATIONAL AIDS SOCIETY>>, 2014; 17 (4 Suppl 3): 19817-19817. 10.7448/IAS.17.4.19817 [http://hdl.handle.net/10807/61162]

Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre

Borghetti, Alberto;Mondi, Annalisa;Gagliardini, Roberta;Ciccarelli, Nicoletta;D'Avino, Alessandro;Pallavicini, Federico;Cauda, Roberto;De Luca, Andrea;Fabbiani, Massimiliano;Di Giambenedetto, Simona
2014

Abstract

According to recent evidence about boosted protease inhibitors (PIs/r)-simplified regimens, the combination of 3TC and DRV/r 800/100 mg could represent a feasible option for optimizing antiretroviral therapy (ART) in treatment-experienced HIV+ patients.
2014
Inglese
Borghetti, A., Mondi, A., Piccoli, B., Gagliardini, R., Lamonica, S., Ciccarelli, N., D'Avino, A., Pallavicini, F., Cauda, R., De Luca, A., Fabbiani, M., Di Giambenedetto, S., Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre, Abstract de <<HIV Drug Therapy Glasgow Congress 2014>>, (Glasgow, 02-06 November 2014 ), <<JOURNAL OF THE INTERNATIONAL AIDS SOCIETY>>, 2014; 17 (4 Suppl 3): 19817-19817. 10.7448/IAS.17.4.19817 [http://hdl.handle.net/10807/61162]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/61162
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 8
social impact